Inhibrx Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Revenue	1.63	1.63	1.32
Revenue Growth (YoY)	-	24.26%	-
Cost of Revenue	136.36	130.13	101.6
Gross Profit	-134.72	-128.5	-100.29
Selling, General & Admin	27.7	24.25	15.04
Operating Expenses	27.7	24.25	15.04
Operating Income	-162.42	-152.75	-115.32
Earnings From Equity Investments	-1.63	-1.63	-
Currency Exchange Gain (Loss)	0.01	-	-
Other Non Operating Income (Expenses)	-0.58	-0.58	0
EBT Excluding Unusual Items	-164.63	-	-
Gain (Loss) on Sale of Assets	0	-	-
Pretax Income	-164.62	-154.96	-115.32
Income Tax Expense	0	0	0
Net Income	-164.63	-154.96	-115.33
Net Income to Common	-164.63	-154.96	-115.33
Free Cash Flow	-148.07	-133.6	-91.5
Operating Margin	-9940.02%	-9348.04%	-8769.81%
Free Cash Flow Margin	-9061.87%	-8176.25%	-6957.95%
EBITDA	-161.16	-151.56	-114.1
D&A For EBITDA	1.26	1.19	1.23
EBIT	-162.42	-152.75	-115.32
Revenue as Reported	1.63	1.63	1.32

Source: S&P Capital IQ. Standard template.